No More Pills, No More Struggles: Korean Innovation Transforms How Kids Approach Growth Support
Korean patch Hautuki ends supplement battles. Kids manage growth support independently through bedtime application. Unlike oral supplements 60% resist, transdermal system delivers nutrients through skin over 8-10 hours. Emma Chen, 9, went from hiding at vitamin time to proudly applying patches. 'Now it's drama-free,' says Hong Kong mother.
HONG KONG - Every evening at 8 PM, 9-year-old Emma Chen used to hide in her bedroom, dreading the nightly battle with her mother over growth vitamins. The familiar scene played out in households across Asia: tears, negotiations, and ultimately, a frustrated parent watching their child reluctantly swallow yet another pill.
Today, Emma looks forward to bedtime. She proudly applies a small patch near her arm – a routine she now manages entirely on her own. 'I don't have to taste anything yucky anymore,' she explains, while her mother watches with visible relief.
Emma's transformation represents a growing trend among families discovering Hautuki, a Korean-developed patch-based growth support system that's quietly revolutionizing how children approach their health routines.
Nine-year-old Emma applies her Hautuki patch independently before bedtime - a routine she now manages entirely on her own.
The Daily Battle Millions of Parents Know Too Well
For parents concerned about their child's growth, the statistics paint a challenging picture. Industry research suggests that up to 60% of children regularly resist taking oral supplements, creating a cycle of stress that often defeats the purpose of growth support entirely.
'We were spending more energy fighting about vitamins than actually helping our child grow,' says Jennifer Wong, a Hong Kong mother of two.
Online parent forums are filled with similar stories: children who gag at the sight of pills, families who've tried every flavored vitamin on the market, and parents who eventually give up on supplementation altogether.
When Kids Take Control
The breakthrough came when Custics Corporation, a Seoul-based biotechnology company, asked a different question: instead of making supplements easier for parents to give, what if children could manage their growth routine independently?
Their answer was Hautuki – a transdermal patch that delivers nutrients through the skin, eliminating the need for swallowing, tasting, or parental intervention.
'When children feel ownership over their health choices, compliance becomes natural rather than forced,' explains Dr. Sarah Kim, a pediatric nutritionist who has observed the product's impact.
The technology works through controlled absorption via the skin, bypassing the digestive system entirely. Children simply apply one patch before bedtime – a process most can master independently within days.
The Science of Consistency
Traditional oral supplements face what researchers call the 'compliance gap' – the difference between prescribed and actual intake. Even motivated families struggle to maintain perfect supplement routines, with missed doses occurring an average of 2-3 times per week.
Hautuki's transdermal delivery system provides steady nutrient absorption over 8-10 hours, creating more consistent blood levels than traditional oral supplements that create peaks and valleys in nutrient availability.
'The patch doesn't just solve the compliance problem,' notes Dr. Michael Chang, a Hong Kong pediatrician. 'It actually provides more stable nutrient delivery than oral supplements, even when those are taken perfectly.'
A Regional Success Story
Since launching in South Korea, Hautuki has expanded across major Asian markets, with Hong Kong representing one of its fastest-growing segments. Local distributors report that word-of-mouth referrals drive much of the product's growth.
'Asian parents have always been proactive about their children's growth, but they're increasingly looking for solutions that reduce family stress while maintaining effectiveness,' says wellness industry analyst Lisa Park. " Hautuki hits both targets.'
Changing the Conversation
Perhaps most significantly, Hautuki is changing how families talk about growth support. Instead of viewing supplementation as something imposed by parents, children increasingly see it as a personal routine they can manage independently.
'My daughter actually reminds me when it's time to reorder patches,' laughs Maria Santos, a Hong Kong expatriate mother. 'She's taken complete ownership of her growth routine.'
Child psychologists note that when children successfully manage health routines on their own, it builds confidence and establishes positive patterns for lifelong self-care.
The Future of Family Health
As Hautuki continues its expansion across Asia, industry observers are watching whether its success signals broader changes in pediatric health products. The emphasis on child autonomy and stress reduction represents a departure from traditional approaches.
'We're seeing the emergence of 'child-centric' health products,' explains healthcare innovation researcher Dr. James Liu. 'Companies are asking how to make children more effective at managing their own health.'
For families like the Chens, the change has been transformative. Emma now views her nightly patch application as a sign of growing up, not a medical chore.
'Growth support used to be about pills, schedules, and arguments,' reflects Jennifer Wong. 'Now it's just part of life – simple, effective, and completely drama-free.'
As more families discover patch-based solutions, the days of supplement struggles may soon become a thing of the past, replaced by a new generation of children who approach their health with confidence and independence.
Media Contact
Company Name: Glovertise
Contact Person: Erick
Email: Send Email
Phone: 01091916367
Address:7/F TOWER 2 SOUTH SEAS CTR 75 MODY RD #706
City: HONG KONG
State: TSIM SHA TSUI
Country: HongKong
Website: https://hautuki.hk
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: No More Pills, No More Struggles: Korean Innovation Transforms How Kids Approach Growth Support

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
2 hours ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).


Medscape
3 hours ago
- Medscape
DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo
The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for autologous stem cell transplant. A complete response letter from the FDA stated that Genentech's phase 3 STARGLO trial did not provide sufficient evidence to support the proposed second-line DLBCL indication for the T cell engaging bispecific antibody in the US, according to a Genentech statement. However, a conditional FDA approval in the third-line or greater setting remains in place. FDA's decision regarding second-line glofitamab aligns with an advisory committee vote in May, which cited a lack of US patient representation in the trial. The Oncologic Drugs Advisory Committee (ODAC) voted 8-1 against recommending approval, as reported by Medscape Medical News . The FDA asked for ODAC review over concerns that nearly half of the STARGLO participants were from Korea, Taiwan, and China, with most of the remaining participants coming from Europe and Australia. Only 25 US patients were included. Outcomes among Asian vs non-Asian patients differed, with a strong trend toward worse overall survival (OS), rates in White patients and patients from Europe and the US, despite a strong overall 0.59 hazard ratio for OS. Similar trends were observed for progression-free survival and complete response rates. At the time, the FDA said the low US enrollment 'limits the agency's ability to assess the applicability of the study results to a US patient population,' and cited additional concerns regarding comparator drugs used in the trial, according to meeting documents. 'While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for US patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting,' Genentech's Chief Medical Officer and head of Global Product Developments, Levi Garraway, MD, PhD, said in the company statement regarding the sBLA rejection. 'We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy.' 'For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount,' added Jeremy Abramson, MD, the principle STARGLO investigator and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, Boston. Abramson stressed that in the STARGLO trial, the glofitamab combination therapy improved OS, which 'could have a positive impact for patients earlier in their treatment journey.' The regimen is currently approved for this indication in more than 35 countries. It is approved in more than 60 countries for third-line or greater treatment of DLBCL, including in the US where the FDA granted accelerated approval in 2023. STARGLO was also intended as a post-marketing confirmatory study to support conversion of the accelerated approval to full approval, Genentech noted. Results were published in 2024 in The Lancet, and 2-year follow-up data showing sustained overall improvements in the primary and secondary endpoints were presented at 2025 American Society of Clinical Oncology Meeting. Genentech said the regimen is currently being investigated in combination with other agents as a first-line treatment for DLBCL in the phase 3 SKYGLO study.
Yahoo
7 hours ago
- Yahoo
Amity Innovation Incubator's Investor Pitch Day Showcases India's Next Generation of Disruptive Startups
NOIDA, India, July 24, 2025 /PRNewswire/ -- The Amity Innovation Incubator, a pioneering concept among Indian universities aimed at nurturing entrepreneurial endeavours, proudly hosted its Investor Pitch Day, bringing together a powerful constellation of emerging startups and top-tier investors for an exciting day of live pitches, strategic networking, and growth-focused dialogue. With over 1100+ startups incubated and accelerated, the Amity Innovation Incubator, which recently won AABI's 'Incubator of the Year Award', continues to drive its mission to accelerate India's entrepreneurial momentum. The July 2025 Pitch Day marked a significant milestone with 10 high-potential startups presenting cutting-edge solutions across sectors like health tech, AI, fintech, and social impact. Participating startups included: Lark – India's only API-first credit infrastructure layer for the $5T+ investment ecosystem, enabling embedded lending against securities across fintech, wealth tech, etc. Livofy – A full-stack chronic care platform delivering personalized, integrative treatment for lifestyle disorders like diabetes, thyroid, and PCOS, serving 7500+ patients. Torchit – A social-tech enterprise dedicated to empowering people with disabilities (PwDs) through affordable, innovative, assistive technologies. CYVIA – An enterprise-grade security brain for LLMs, transforming every prompt into a real-time, auditable, policy-enforced event. Profrea – A tech-enabled platform that transforms underutilized clinics into pay-per-use medical workspaces, boosting clinic utilization, reducing CAPEX, and creating a new revenue stream in outpatient healthcare. Genetico – Asia's first clinical decision support platform focused on rare and genetic diseases, enabling clinicians to diagnose and manage complex conditions through an AI-powered software, combining pedigree analytics, Human Phenotype Ontology-based differential diagnosis, and deep data tools. Sconto – A student-first verification and commerce platform that connects verified Indian college students with curated brand discounts, offers, and experiences, through its proprietary KYS engine. AICodePro – An AI-powered headless commerce platform built for D2C brands and online sellers. Blyp – An AI-driven smart parking and mobility platform offering guaranteed parking in under 2 minutes. Medino's – A full-stack, phygital healthcare platform delivering doctor consults, e-prescriptions, and medicines within 30 minutes. Esteemed investors included: Vaibhav Jain at Google, focusing on startup and VC collaboration Amit Sharma from Cactus Venture Partners, which has invested in startups like Kapture CRM, Vitraya Technologies, AMPM, Blyp, Loham, and more Addison Appu from Thikuvate Capital, which has invested in startups like Petmojo, Kivi, Zippee, Good Monk, and Strive Representatives from BEENEXT, Caret Capital, AdvantEdge, Lead Invest, 8X Ventures, IIFL Capital, and Ankur Capital, among others, also participated. Dr. Aseem Chauhan, President, Amity Innovation Incubator, remarked, "Investor Pitch Day is more than a showcase; it's a catalytic platform for India's most promising startups to meet vision-aligned investors. This event reflects the vibrancy and resilience of India's startup ecosystem." The day featured live pitches, one-on-one investor meetings, and mentoring sessions, offering a dynamic environment for entrepreneurs to receive real-time feedback and forge meaningful connections. The event concluded with multiple expressions of interest and ongoing due diligence, indicating a high level of engagement from the investor community. Mr. Ojasvi Babber, CEO of Amity Innovation Incubator, expressed his gratitude to the participating investors for their mentorship and support. About Amity Innovation Incubator Amity Innovation Incubator has been supported by NITI Aayog, DST, MeitY, MSME, iDEX, and StartinUP, strengthening our commitment to fostering innovation. All the startups that presented have been supported by Amity Innovation Incubator through different programs. These programs include Atal Innovation Mission, the Ministry of Electronics and Information Technology, IDEX, and many others. Amity Innovation Incubator has built a robust and holistic support system for startups and entrepreneurs, offering strategic mentorship, infrastructure, and investor access through every stage of their entrepreneurial journey. Through Amity Capital Ventures (ACV), the incubator enables eligible startups to seamlessly connect with a powerful network of High Net-Worth Individuals (HNIs) and renowned VC Funds. With 18+ successful exits and over 120 startup investments facilitated, Amity Innovation Incubator not only nurtures innovation but also ensures promising ventures are fully equipped—technically, strategically, and financially—for scalable growth. Photo: View original content to download multimedia: